Paras Biopharmaceuticals Finland Oy is a Finnish biopharmaceuticals company started in 2012. Comprising of protein scientists, bioprocess engineers and technologists, Paras Biopharmaceuticals’ team has strong experience in developing biologics in a most efficient manner.
Company main activities & offerings are in 3 major areas:
Contract development & recombinant biologics manufacturing in microbial systems (CDMO) – Company offers small scale (10L), medium sale (150L) & large scale (750L or more) production services.
Offering Development of Biosimilar Technologies and Partnership - Paras Biopharmaceuticals is actively engaged in research & development and is offering partnership for further development (including clinical development) on the following biosimilars: Recombinant Teriparatide (Forteo® Biosimilar), Recombinant IL1-RA /Anakinra (Anakinra Biosimilar), Analog Insulin Aspart and Recombinant Romiplostim (Nplate® Biosimilar). Further biologics are in the pipeline*. Anakinra is marketed and sold by Swedish Orphan Biovitrum AB under the name Kineret®. *Forteo®, Kineret® & Nplate® are registered trademarks of Eli Lilly USA, Swedish Orphan Biovitrum AB and Amgen USA, respectively.
Development of Recombinant expression systems and process technologies for biologics and biosimilars - Due to its own technologies, Paras Biopharmaceuticals has achieved efficient and cost-effective ways which would help in the efficient production of some high value biosimilars. This development is based on Paras Bio-pharmaceuticals’ proprietary technology platform which includes Diabrid®, Noblecleav®, Biomultifold® and Cytofold StructQuant® technologies.
Recombinant Bioprocess Enzymes – Paras Biopharmaceuticals has developed and is offering Recombinant Bioprocess enzymes. These include Recombinant Enterokinase (RapidEK®) & Tev Protease (RapidTEV®) which are used in the cleavage of fusion proteins. Paras Biopharmaceuticals is ready to cater to biopharma needs for scale-up / commercial scale production.
Biomultifold® provides an innovative and highly efficient process for the production of recombinant proteins using an E. Coli expression system. Biomultifold® enables to achieve expression levels of multigrams of therapeutic proteins per liter of fermentation.
Learn More »
NobleCleav® is a proprietary technology for efficient processing of recombinant therapeutic peptides and therapeutic proteins. The technology facilitates high level production of authentic biologics by combining high specificity and activity of processing.
Learn More »
Diabrid® Technology is a unique proprietary technology for the expression of recombinant therapeutic proteins and therapeutic peptides. The technology facilitates a higher expression of therapeutic proteins in a manner that enhances the quality and bio effectiveness of the molecules in addition to facilitating post production protocols.
Learn More »
Paras Biopharmaceuticals Finland Oy is an up-and-coming biopharmaceutical technology development company which has successfully developed the Diabrid Platform Technology proprietary for the high level expression of biosimilars in specially designed genetically stable clones.
Learn More »
Paras Biopharmaceuticals Finland Oy offers a wide spectrum of biopharmaceuticals technologies for therapeutic peptides, proteins and process technologies.
Diabrid® Technology
NobleCleav® Technology
Biomultifold® Technology
Cytofold StructQuant® Protein Folding Technology
Paras Biopharmaceuticals
Finland Oy
Kiviharjunlenkki 10
90220 OULU, Finland
+358 44 270 9462
Dr Ashesh Kumar
kumar.ashesh@parasbiopharma.com
+358 (0) 400 207380
Dr Mark Jackson
mark.jackson@parasbiopharma.com
+358 (0) 44 2905993
LinkedIn: Paras Biopharma (Biologics CDMO) Finland
This website uses cookies; by continuing to use this page, you consent to their use. I Understand About Cookies.
